



SUPPLEMENTARY FIGURES



Supplementary Figure 1. FZU-0038-056 does not affect TNBC cell cycle progression. (A) The HCC1806 and HCC1937 breast cancer cells were treated with FZU-0038-056 (5 μ M) for 24 hours. DMSO was used as the negative control. Cells were collected for PI (Propidium iodide) staining and cell cycle analysis after treatment. (B) Quantification of panel A.



Supplementary Figure 2. FZU-0038-056 and cisplatin synergistically suppress HCC1806 cell survival. (A, B) HCC1806 cells were treated with FZU-0038-056 (5 μM) together with cisplatin at indicated dosages for 48 hours. Cells were fixed for SRB analysis after treatment. (C, D) HCC1806 cells were treated with cisplatin (5 μM) together with FZU-0038-056 at indicated dosages for 48 hours. Cells were fixed for SRB analysis after treatment.